“Challenges in Biopharmaceutical Productions” – Community and Education

Begin: 11:45-13:00 CET

Challenges in Biopharmaceutical Production

Prof. Dr. Philipp Wiedemann  // Hochschule Mannheim

Organised as monthly 1-hour-webinars, the ultimate goal of the seminar series “Community and Education in Action” is to assemble like-minded intellectuals and professionals from our community to trade ideas, thoughts, and views related to a specific EIT-Health topic especially focused in the Education Pillar.



To receive the dial-in information, just register via this Eventbrite-Link.

After the series, an e-booklet will be published with the summaries and information of the speakers. Participants can receive a recording of their session after the Video and will have the opportunity to provide their feedback.


About this seminar:

Biopharmaceuticals, predominantly recombinant proteins, are still a relatively new class of pharmaceuticals with the first approvals dating back to the late 1980s. Nevertheless, they have gained considerable attention – since they successfully target severe indications like e.g. cancer – and they are consistently one of the fastest-growing pharmaceutical market segments.

In this talk, we will explore some general principles of biopharmaceuticals and their production and, on this basis, try to elucidate some of the major challenges and changes this exciting and highly interdisciplinary field is currently undergoing.


Our speaker: Philipp Wiedemann:

Philipp Wiedemann studied Biology at the universities of Bonn (Germany), York (UK), and Stanford (USA). He obtained a Ph.D. in Molecular Neuropharmacology at the University of Bonn. Philipp worked for biotech companies in Germany and abroad, amongst others in the large-scale production of biopharmaceuticals. In 2007, he joined Mannheim University of Applied Sciences, where he focuses on teaching and research in cell culture technology, process monitoring, and quality assurance. Additionally, he is Scientific Advisor to the Biotech StartUp Aucteq GmbH.